Colchicine After Electrocardioversion for Atrial Fibrillation

Summary

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.

Eligibility

Inclusion Criteria:

* Age \>18 years
* ECG-documented AF prior to ECV
* Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV
* Ability to give written informed consent

Exclusion Criteria:

* AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV
* Any other rhythm than AF before cardioversion
* Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV
* Known intolerance or hypersensitivity to Colchicine
* Any other absolute indication for Colchicine intake
* Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole)
* Serious gastrointestinal disease (severe gastritis or diarrhea)
* Clinically overt hepatic disease
* Severe renal disease (eGFR\< 30ml/min/1.73m2)
* Clinically significant blood dyscrasia (e.g., myelodysplasia)
* Significant immunosuppression (e.g. due to transplantation or rheumatic disease)
* Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control
* Life expectancy \<1 year

Conditions3

Browse More Trials